Dual drug combination overcomes treatment resistance in mutant liver cancer

Liver cancer cells have learned to cheat death. When researchers at multiple institutions studied hepatocellular carcinoma—the most common form of liver cancer—they discovered that tumors with mutations in a gene called β-catenin were systematically blocking a cellular self-destruct mechanism called ferroptosis. This blockade was making the cancer resistant to existing drugs, and understanding why became the focus of a new study published this summer.

The culprit turned out to be a protein pathway called mTOR, which sits at the center of how cells decide whether to grow or die. When mTOR becomes overactive in these mutant liver cancers, it phosphorylates a protein called 4EBP1, which in turn suppresses ferroptosis—essentially telling cancer cells to ignore the kill signal. Researchers working with cell lines called MHCC97H and SNU449 found that when they treated these cells with rapamycin, a drug that inhibits mTOR, the cancer cells became more sensitive to ferroptosis. But rapamycin alone wasn't enough. The cancer cells had a backup plan.

The team discovered that a variant of 4EBP1 called 4EBP1A4 could work like a molecular crowbar. This variant protein competitively binds to a heat shock protein called HSP90β, displacing another protein called Keap1 from the same binding site. Once freed, Keap1 forms a complex with a protein called Nrf2, which then gets degraded. This chain reaction—displacement, complex formation, degradation—essentially removes a brake on ferroptosis. When researchers introduced 4EBP1A4 into cancer cells alongside rapamycin, the combination became far more potent at killing the tumor cells.

But the real breakthrough came when the team tested a two-drug combination: MLN0128, which inhibits mTOR more broadly than rapamycin, paired with PD901, which blocks a separate pathway called ERK. In laboratory cell cultures, this combination reduced phosphorylated 4EBP1 levels, induced ferroptosis across multiple cancer cell lines, and suppressed tumor cell growth more effectively than any single drug. The researchers then tested this approach in living mice engineered to develop β-catenin-mutant liver cancer. The combination therapy outperformed all other treatment regimens, shrinking tumors significantly.

What makes this finding clinically relevant is that it identifies 4EBP1 as a critical junction point where two major cancer-driving pathways—mTOR and ERK—converge. By hitting both pathways simultaneously, the combination therapy prevents the cancer from compensating when one pathway is blocked. The mTOR pathway tries to activate as a workaround, but the ERK inhibitor prevents that escape route. Meanwhile, ferroptosis, the cell death mechanism that was being suppressed, finally gets activated.

The researchers emphasize that this mechanism appears specific to β-catenin-mutant hepatocellular carcinoma, a subset of liver cancers that has historically been difficult to treat. Standard chemotherapy often fails because these tumors are particularly adept at suppressing ferroptosis. The dual-drug approach offers a rational way to overcome that resistance by targeting the molecular machinery that enables it.

Clinical development of MLN0128 and PD901 as a combination therapy for this patient population is now a logical next step. The study provides a molecular roadmap for why the combination works, which could help researchers predict which patients are most likely to respond and potentially guide the design of even more effective follow-up treatments.